Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA issues complete response letter regarding Byuderon NDA

Oct. 21, 2010

New diacylglycerol O-acyltransferase 1 inhibitors disclosed

Oct. 21, 2010

Treatment begins in phase I/II alpha-1-antitrypsin trial in type 1 diabetes

Oct. 21, 2010

Zealand Pharma's ZP-2307 shows bone anabolic activity in vivo

Oct. 21, 2010

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Oct. 20, 2010

FDA grants fast track status for HPN-100 in urea cycle disorders

Oct. 20, 2010

DiaMedica reports final data from DM-99 study in type 1 diabetes

Oct. 20, 2010

Pfizer presents new GPR119 receptor agonists

Oct. 18, 2010

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Oct. 15, 2010

FDA warns of increased risk of thigh bone fracture with bisphosphonates use

Oct. 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...